ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
129.036,10
-0,07%
S&P 500
5.987,37
0,30%
US Dollar vs BRL
5,7984
-0,03%
Bitcoin
94.664,73
1,70%
Brent Oil
72,675
0,10%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Cue Biopharma Inc (CUE)

  7. Cue Biopharma Inc (CUE) Notícias

CUE

Cue Biopharma (CUE)

Cue Biopharma Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:CUE
DataHoraFonteTítuloCódigoCompanhia
25/11/202410:00GlobeNewswire Inc.Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare ConferenceNASDAQ:CUECue Biopharma Inc
14/11/202418:05GlobeNewswire Inc.Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:CUECue Biopharma Inc
14/11/202418:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CUECue Biopharma Inc
14/11/202418:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CUECue Biopharma Inc
14/11/202410:00GlobeNewswire Inc.Cue Biopharma Announces Strategic Organizational TransitionNASDAQ:CUECue Biopharma Inc
12/11/202410:00GlobeNewswire Inc.Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare ConferenceNASDAQ:CUECue Biopharma Inc
08/11/202415:30GlobeNewswire Inc.Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual MeetingNASDAQ:CUECue Biopharma Inc
07/10/202418:07Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:CUECue Biopharma Inc
04/10/202410:00GlobeNewswire Inc.Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual MeetingNASDAQ:CUECue Biopharma Inc
27/09/202417:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CUECue Biopharma Inc
27/09/202400:26GlobeNewswire Inc.Cue Biopharma Announces Pricing of $12.0 Million Public OfferingNASDAQ:CUECue Biopharma Inc
27/09/202400:10GlobeNewswire Inc.Cue Biopharma Announces Proposed Public OfferingNASDAQ:CUECue Biopharma Inc
10/09/202417:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CUECue Biopharma Inc
09/09/202409:00GlobeNewswire Inc.Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business OfficerNASDAQ:CUECue Biopharma Inc
05/09/202417:00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CUECue Biopharma Inc
05/09/202417:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CUECue Biopharma Inc
03/09/202409:00GlobeNewswire Inc.Cue Biopharma to Present at The Promise of Interleukin-2 Therapy ConferenceNASDAQ:CUECue Biopharma Inc
28/08/202417:00Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:CUECue Biopharma Inc
19/08/202417:05GlobeNewswire Inc.Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:CUECue Biopharma Inc
13/08/202409:00GlobeNewswire Inc.Cue Biopharma to Host Business Update Call and WebcastNASDAQ:CUECue Biopharma Inc
25/07/202417:05GlobeNewswire Inc.Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital RequirementsNASDAQ:CUECue Biopharma Inc
04/06/202409:00GlobeNewswire Inc.Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual MeetingNASDAQ:CUECue Biopharma Inc
03/06/202409:00GlobeNewswire Inc.Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024NASDAQ:CUECue Biopharma Inc
24/05/202417:00Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CUECue Biopharma Inc
09/05/202417:05GlobeNewswire Inc.Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:CUECue Biopharma Inc
08/05/202409:00GlobeNewswire Inc.Cue Biopharma to Present at the 20th Annual PEGS Boston SummitNASDAQ:CUECue Biopharma Inc
07/05/202409:00GlobeNewswire Inc.Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences ConferenceNASDAQ:CUECue Biopharma Inc
24/04/202411:01GlobeNewswire Inc.Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:CUECue Biopharma Inc
08/04/202417:05GlobeNewswire Inc.Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business HighlightsNASDAQ:CUECue Biopharma Inc
29/02/202412:00GlobeNewswire Inc.Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers SymposiumNASDAQ:CUECue Biopharma Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:CUE

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
SEQL3
Sequoia Logistica e Tran... ON
BOV
TELB4
TELEBRAS PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Economize até 60%* para TRADER PLUS

1 ano 40%, 2 anos 50% e *3 anos 60%

*Ao longo de 3 anos $ 1475.65 apenas $ 590.25